Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Oncologist Retrieve available abstracts of 76 articles: HTML format

Single Articles

September 2025
1. LIANG J, Waliany S, Do A, Peterson JL, et al
   ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC.
   Oncologist. 2025;30:oyaf217.
   PubMed     Abstract available
   
   
   
2. LI X, Gong W, Yao X, Gao Y, et al
   Effects of magnesium concentration on the regulation of nutrition and inflammation in nutritional support for cancer patients.
   Oncologist. 2025;30:oyaf211.
   PubMed     Abstract available
   
   
   
3. LIU Y, Liu F, Wang C, Yan Y, et al
   Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis.
   Oncologist. 2025;30:oyaf266.
   PubMed     Abstract available
   
   
   
4. LISBERG A, Huppert LA, Halmos B, Ledezma B, et al
   Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management.
   Oncologist. 2025;30:oyaf225.
   PubMed     Abstract available
   
   
   August 2025
5. WANG J, Sajeev G, Chai X, Takundwa R, et al
   Efficacy Outcomes Between Tarlatamab and Real-World Physicians' Choice of Therapies for Previously Treated Extensive Stage Small Cell Lung Cancer.
   Oncologist. 2025 Aug 21:oyaf256. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. VELCHETI V, Sun X, Hanna M, Zimmerman NM, et al
   Predictors of outcomes in advanced non-small cell lung cancer treated with pembrolizumab maintenance.
   Oncologist. 2025;30:oyaf070.
   PubMed     Abstract available
   
   
   
7. CHAE YK, Oh Y, Kim L, Park JH, et al
   Bilateral orthotopic lung transplantation for the patient with lung-limited invasive mucinous adenocarcinoma: a case-based literature review.
   Oncologist. 2025;30:oyae263.
   PubMed     Abstract available
   
   
   July 2025
8. WANG L, Gao M, Wang T, Cui P, et al
   First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study.
   Oncologist. 2025;30:oyaf155.
   PubMed     Abstract available
   
   
   
9. ZHOU C, Huang R, Yuan Y, Schnell P, et al
   Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.
   Oncologist. 2025;30:oyaf177.
   PubMed     Abstract available
   
   
   
10. FLOREZ N, LeBoeuf NR, Rotow J, Marks JA, et al
    Mitigation and management of adverse events associated with amivantamab therapy.
    Oncologist. 2025;30:oyaf194.
    PubMed     Abstract available
    
    
    
11. TM A, Raj L, Nair P, Vincent A, et al
    Utility And Real-World Clinical Outcomes Of Next-Generation Sequencing In Advanced Non-Small-Cell Lung Cancer In South Indian Population.
    Oncologist. 2025 Jul 1:oyaf168. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
12. ISAWA T, Togashi S, Taguri M, Toi Y, et al
    Cardiovascular adverse events in patients with lung cancer treated with immune checkpoint inhibitors: a nationwide database study.
    Oncologist. 2025;30:oyaf151.
    PubMed     Abstract available
    
    
    
13. WANG W, Xu X, Liu H, Cui Y, et al
    The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.
    Oncologist. 2025;30:oyaf114.
    PubMed     Abstract available
    
    
    
14. LI G, Greene SB, Kaur B, Keller-Evans RB, et al
    Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer.
    Oncologist. 2025;30:oyaf159.
    PubMed     Abstract available
    
    
    
15. FRISCH A, Martin E, Kim SY, Riess JW, et al
    KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape.
    Oncologist. 2025;30:oyaf153.
    PubMed     Abstract available
    
    
    May 2025
16. GIRARD N, Xu Q, Camidge DR, Baijal S, et al
    Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101.
    Oncologist. 2025;30:oyaf029.
    PubMed     Abstract available
    
    
    
17. LIN VTG, Ma E, Jain N, Xia Z, et al
    A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment.
    Oncologist. 2025;30:oyaf067.
    PubMed     Abstract available
    
    
    
18. XING P, Pu X, Zhou Y, Liu Z, et al
    Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC and brain metastasis: a multicenter cohort study.
    Oncologist. 2025;30:oyaf079.
    PubMed     Abstract available
    
    
    
19. HU X, Melson JW, Pan SS, Salei YV, et al
    Palliative and end-of-life care in Asian and White patients with metastatic lung cancer.
    Oncologist. 2025;30:oyaf065.
    PubMed     Abstract available
    
    
    April 2025
20. BAUTISTA-GONZALEZ E, Munoz Rocha TV, Soto-Perez-de-Celis E, Vindrola-Padros C, et al
    Treatment delays in patients with lung cancer: a retrospective study conducted at the National Cancer Institute of Mexico between 2004 and 2021.
    Oncologist. 2025;30:oyae358.
    PubMed     Abstract available
    
    
    March 2025
21. PENAULT-LLORCA F, Socinski MA
    Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations.
    Oncologist. 2025 Mar 24:oyae357. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. LEVI A, Blais E, Davelaar J, Ebia MI, et al
    Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database.
    Oncologist. 2025;30:oyaf007.
    PubMed     Abstract available
    
    
    
23. GRAY Z, Levonyak N, Jia L, Ahn R, et al
    Managing elderly patients with dual metastatic cancers-navigating diagnostic and treatment challenges.
    Oncologist. 2025;30:oyaf026.
    PubMed     Abstract available
    
    
    
24. VITALE A, Vita E, Stefani A, Cancellieri A, et al
    Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report.
    Oncologist. 2025;30:oyaf030.
    PubMed     Abstract available
    
    
    
25. LI Y, Li C, Zhao X, Li Y, et al
    Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial.
    Oncologist. 2025;30:oyae336.
    PubMed     Abstract available
    
    
    
26. VON ITZSTEIN MS, Rashdan S, Dahlberg SE, Gerber DE, et al
    Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer.
    Oncologist. 2025;30:oyaf036.
    PubMed     Abstract available
    
    
    
27. RADWAN A, Jani CT, Al Omari O, Patel M, et al
    The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients.
    Oncologist. 2025;30:oyae279.
    PubMed     Abstract available
    
    
    February 2025
28. LEITE DA SILVA LF, Saldanha EF, de Menezes JSA, Halamy Pereira L, et al
    Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Oncologist. 2025;30:oyae344.
    PubMed     Abstract available
    
    
    
29. SALDANHA EF, Cordeiro de Lima VC, Fares A, Corassa M, et al
    Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP).
    Oncologist. 2025;30:oyae347.
    PubMed     Abstract available
    
    
    
30. RESTIVO L, Rochigneux P, Bouhnik AD, Arciszewski T, et al
    Patients' psychosocial attributes and aggressiveness of cancer treatments near the end of life.
    Oncologist. 2025;30:oyae317.
    PubMed     Abstract available
    
    
    January 2025
31. SKOULIDIS F, Li BT, Hochmair M, Govindan R, et al
    Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.
    Oncologist. 2025;30:oyae356.
    PubMed     Abstract available
    
    
    
32. ARNDT A, Neumann C, Riecke A, Bauer A, et al
    Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.
    Oncologist. 2025;30:oyae143.
    PubMed     Abstract available
    
    
    December 2024
33. MEHLMAN C, Swalduz A, Monnet I, Morin C, et al
    COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.
    Oncologist. 2024 Dec 26:oyae312. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. CHEN LN, Ma X, Herzberg B, Henick BS, et al
    Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer.
    Oncologist. 2024 Dec 19:oyae315. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. LEE HJ JR, Boscardin J, Walter LC, Smith AK, et al
    Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.
    Oncologist. 2024 Dec 9:oyae349. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2024
36. NAIDOO J, Johnson DB, Doran C, Wang Y, et al
    Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors.
    Oncologist. 2024 Nov 20:oyae318. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. SADAGOPAN N, Komlodi-Pasztor E, Veytsman I
    Immunotherapy benefits for large brain metastases in non-small cell lung cancer.
    Oncologist. 2024 Nov 15:oyae314. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
38. ARRIETA O, Ramos-Ramirez M, Garces-Flores H, Cabrera-Miranda LA, et al
    Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries.
    Oncologist. 2024 Oct 19:oyae272. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. CAVAGNA RO, Escremim de Paula F, Berardinelli GN, Bonatelli M, et al
    Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients who have never smoked: implications for targeted therapies.
    Oncologist. 2024;29:e1419-e1424.
    PubMed     Abstract available
    
    
    September 2024
40. SHAW J, Pundole X, Balasubramanian A, Anderson ES, et al
    Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer.
    Oncologist. 2024 Sep 30:oyae234. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. APTER L, Sharman Moser S, Gazit S, Chodick G, et al
    Healthcare resource utilization and associated cost in patients with metastatic non-small cell lung cancer treated in the immunotherapy era.
    Oncologist. 2024 Sep 28:oyae240. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. SEBASTIAN NT, Stokes WA, Behera M, Jiang R, et al
    The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Oncologist. 2024 Sep 25:oyae262. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. 
    Correction to: Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2024 Sep 24:oyae253. doi: 10.1093.
    PubMed    
    
    
    
44. ALVES DE SOUZA G, Dornellas DMS, Campregher PV, Teixeira CHA, et al
    Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report.
    Oncologist. 2024;29:764-767.
    PubMed     Abstract available
    
    
    
45. FLOREZ N, Patel SP, Wakelee H, Bazhenova L, et al
    Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
    Oncologist. 2024 Sep 5:oyae228. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
46. DHAWALE TM, Bhat RS, Johnson PC, Srikonda S, et al
    Telemedicine-based serious illness conversations, healthcare utilization, and end of life care among patients with advanced lung cancer.
    Oncologist. 2024 Aug 29:oyae216. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. BOULANGER MC, Schneider JL, Lin JJ
    Advances and future directions in ROS1 fusion-positive lung cancer.
    Oncologist. 2024 Aug 23:oyae205. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. MACK PC, Keller-Evans RB, Li G, Lofgren KT, et al
    Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
    Oncologist. 2024;29:e984-e996.
    PubMed     Abstract available
    
    
    July 2024
49. FALADE A, Zubiri L, Wu CY, Perlman K, et al
    Immune-related adverse events requiring hospitalization in patients with lung cancer: implications and insights.
    Oncologist. 2024 Jul 26:oyae189. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. MEYER ML, Hirsch FR, Bunn PA, Ujhazy P, et al
    Calls to action on lung cancer management and research.
    Oncologist. 2024 Jul 13:oyae169. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. MEHTA GU, Vellanki PJ, Ren Y, Amatya AK, et al
    FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
    Oncologist. 2024 Jul 6:oyae151. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. CHANG AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, et al
    The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
    Oncologist. 2024;29:609-618.
    PubMed     Abstract available
    
    
    
53. CHENG W, Xu T, Yang L, Yan N, et al
    Dramatic response to crizotinib through MET phosphorylation inhibition in rare TFG-MET fusion advanced squamous cell lung cancer.
    Oncologist. 2024 Jul 2:oyae166. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
54. JAYAKRISHNAN R, Kwiatkowski DJ, Rose MG, Nassar AH, et al
    Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations.
    Oncologist. 2024 Jun 22:oyae091. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. NEAL JW, Minichiello K, Brennick R, Huang RSP, et al
    A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
    Oncologist. 2024;29:e843-e847.
    PubMed     Abstract available
    
    
    May 2024
56. VALLEJO J, Singh H, Larkins E, Drezner N, et al
    Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.
    Oncologist. 2024;29:422-430.
    PubMed     Abstract available
    
    
    April 2024
57. CHEN HW, Kuo YW, Chen CY, Chang CH, et al
    Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
    Oncologist. 2024;29:e498-e506.
    PubMed     Abstract available
    
    
    
58. ARRIOLA E, Jaal J, Edvardsen A, Silvoniemi M, et al
    Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer.
    Oncologist. 2024;29:e561-e569.
    PubMed     Abstract available
    
    
    
59. ALLENDE S, Turcott JG, Verastegui E, Rodriguez-Mayoral O, et al
    Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial.
    Oncologist. 2024 Apr 1:oyae050. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
60. XU Y, Ji H, Zhang Y, Xiong L, et al
    Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2024 Mar 25:oyae052. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. PASELLO G, Lorenzi M, Scattolin D, Del Conte A, et al
    Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
    Oncologist. 2024 Mar 23:oyae043. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. XU Y, Wen N, Haddad RI, Sonis ST, et al
    Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles.
    Oncologist. 2024;29:e382-e391.
    PubMed     Abstract available
    
    
    February 2024
63. STRICKER T, Jain N, Ma E, Yu E, et al
    Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
    Oncologist. 2024 Feb 28:oyae022. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. BRIA E, Morgillo F, Garassino MC, Ciardiello F, et al
    Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
    Oncologist. 2024 Feb 20:oyad342. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2024
65. KATAYAMA Y, Yamada T, Sawada R, Kawachi H, et al
    Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
    Oncologist. 2024 Jan 18:oyae001. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. GERBER DE, Wang Y, Ramalingam SS, Bhalla S, et al
    Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
    Oncologist. 2024 Jan 11:oyad335. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. WANG H, Fan Z, Yang X, Wu Q, et al
    Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-small Cell Lung Cancer: A Case Report.
    Oncologist. 2024 Jan 10:oyad339. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. BONANNO L, Lorenzi M, Massa D, De Nuzzo M, et al
    Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
    Oncologist. 2024;29:e118-e130.
    PubMed     Abstract available
    
    
    
69. HORIUCHI K, Ikemura S, Sato T, Shimozaki K, et al
    Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Oncologist. 2024;29:e108-e117.
    PubMed     Abstract available
    
    
    
70. JORDAN J, Maki RG
    The Weighted Toxicity Score: Confirmation of a Simple Metric to Communicate Toxicity in Randomized Trials of Systemic Cancer Therapy.
    Oncologist. 2024;29:67-74.
    PubMed     Abstract available
    
    
    November 2023
71. 
    Correction to: Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Nov 24:oyad316. doi: 10.1093.
    PubMed    
    
    
    
72. STRICKLER JH, Yoshino T, Stevinson K, Eichinger CS, et al
    Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
    Oncologist. 2023;28:e981-e994.
    PubMed     Abstract available
    
    
    October 2023
73. HU X, Melson JW, Pan SS, Salei YV, et al
    Screening, Diagnosis, and Initial Care of Asian and White Patients With Lung Cancer.
    Oncologist. 2023 Oct 5:oyad272. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. SILVERSTEIN J, Wright F, Wang M, Young A, et al
    Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.
    Oncologist. 2023;28:e950-e959.
    PubMed     Abstract available
    
    
    September 2023
75. SHANG X, Zhang C, Kong R, Zhao C, et al
    Construction of a Diagnostic Model for Small Cell Lung Cancer Combining Metabolomics and Integrated Machine Learning.
    Oncologist. 2023 Sep 14:oyad261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al
    Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.
    Oncologist. 2023 Sep 5:oyad245. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.